Got it, thanks and Do you think it’s fair to compare this company with Biocon only if we specifically take their biology business and compare with Biocon, so if you see Biocon being one of the first, well established and well experience player isn’t doing well in their biologic division the business hasn’t done anything since a long time even though they are into this biologic segment and had few launches since last 3 years even though market hasn’t been rewarding it very well or it’s not been well received (I know their fundamentals aren’t improving due to huge investments required upfront and a long gestation period before they could even Monetize them) by market or investors even today investors are shying away from this space even when there is huge potential in the future considering the numbers of expiry of patents, High Margins, TAM, high entry barriers due to patent or high R&D time and expense. why do we think markets will be rewarding SHILPA Medicare well or even better than Biocon given that they are the early movers with many ANDAs in the pipeline.
Is it fair to compare just on their Biologic business or are we being quite optimistic on their growth in their biologic business?
Appreciate your thoughts on this.
| Subscribe To Our Free Newsletter |
